OM
GYRE icon

Opaleye Management’s Gyre Therapeutics GYRE Stock Holding History

Opaleye Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-166,667
Closed -$6.3M – 54
2021
Q1 		$6.3M Buy
166,667
+146,827
+740% +$6.71M 0.93% 32
2020
Q4 		$939K Buy
+19,840
New +$859K 0.12% 54

Other funds holding GYRE

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Opaleye Management's GYRE Position: Q2 2021 in Review

Opaleye Management sold out of Gyre Therapeutics (GYRE) in Q2 2021, closing a stake of 166,667 shares — an estimated $6.3M sold.

Opaleye Management first reported a position in GYRE in Q4 2020 and held it in 2 quarters. The position peaked at $6.3M in Q1 2021. 69 funds tracked by Wall St. Rank hold GYRE as of Q2 2021.

  • Opaleye Management reported no remaining Gyre Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Opaleye Management sold 166,667 Gyre Therapeutics shares in Q2 2021, an estimated $6.3M.
  • Opaleye Management first reported a position in Gyre Therapeutics in Q4 2020 and held it in 2 quarters.
  • Opaleye Management's Gyre Therapeutics position peaked at $6.3M in Q1 2021.
  • 69 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2021.

Based on Opaleye Management's 13F filing for Q2 2021, filed 16 Aug 2021.